Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? |
| |
Authors: | Edoardo Mannucci Matteo Monami |
| |
Institution: | 1. Department of Cardiovascular Medicine, Section of Geriatric Cardiology, Azienda Ospedaliero-Universitaria Careggi, Via delle Oblate 4, 50141, Florence, Italy
|
| |
Abstract: | Thiazolidinediones (TZDs), agonists of the nuclear receptor peroxisome proliferator-activated receptor-γ, induce the expression
of many genes, including several enzymes and transporters involved in glucose and lipid metabolism. Although the efficacy
of TZDs on blood glucose control in type 2 diabetes is not questionable, their cardiovascular effects have been debated, with
beneficial or harmful actions suggested by different authors. This article reviews the available clinical evidence on the
cardiovascular effects of TZDs, discussing possible mechanisms underlying the observed effects and suggesting some directions
for future research. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|